glofitamab,Obinutuzumab 
roche
['glofitamab', 'lymphoma']
more from 's website re #asco22 presentation: 51.6% of patients in the clinical trials had an overall response (a partial or complete response) to lymphoma drug glofitamab. 77.6% of the patients w/ a "complete response" was ongoing at 12 months. 
Founder of Cambridge BioPartners, Inc. I'm also @PearlF on Clubhouse.